
We solved TrkB,
a previously undruggable target
Over 30 years of scientific work and 34,000+ publications validate the target
Meet the team
Our experienced multidisciplinary international team includes the original inventors and qualified drug developers from the global pharmaceutical industry partnering with leading drug discovery CROs.
-
Jami Mandelin
Co-founder, CEO
14y of commercial & R&D experience from Faron Pharmaceuticals, Novartis, Roche -
Georgios Trichas
Chief Business Officer
15y of commercial experience from Achilles Therapeutics, Wellcome Trust -
Matti Karvonen
Chief Medical Officer
20y of drug development experience from Orion Pharma, Faron Pharmaceuticals, Roche, Biogen -
Peter Gallagher
Co-founder, Medicinal Chemistry Lead
36y of medicinal chemistry experience in CNS drug discovery from Eli Lilly with 20+ patents
-
Giray Enkavi
Co-founder, Principal Scientist Modeling
20y of biophysics and biomodelling experience from University of Illinois and University of Helsinki -
Rafael Moliner
Co-founder, Biology Lead
12y of experience in TrkB biology from University of Helsinki -
Tim Schulz-Utermoehl
DMPK Lead
23y of neuroscience DMPK experience from MSD, AstraZeneca UK, Shire UK, Sygnature
-
Eero Castrén
Co-founder, Board member
Professor, Research Director, Neuroscience Center, University of HelsinkiWorld-leader in BDNF and TrkB biology and antidepressant drug research
Landmark 2023 Nature Neuroscience paper demonstrated role of TrkB receptor in mediating the positive effects of psychedelics
241 papers published with more than 28,000 citations
-
Ilpo Vattulainen
Co-founder, Board member
Professor in Biological Physics, University of HelsinkiWorld-leader in in-silico biomolecular simulations and AI/ML
Revealed the structure of TrkB embedded in cholesterol enriched membranes dimers with and without different ligands
300+ papers published with more than 26,000 citations